Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

26.14
+0.08500.33%
Volume:171.80K
Turnover:4.47M
Market Cap:1.55B
PE:-10.88
High:26.42
Open:25.99
Low:25.18
Close:26.05
52wk High:40.65
52wk Low:11.70
Shares:59.49M
Float Shares:35.21M
Volume Ratio:0.44
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:4.40
PE(LYR):-12.99

Loading ...

Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Aug 11

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42

MT Newswires Live
·
Aug 11

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Tyra Biosciences price target lowered to $42 from $44 at Jefferies

TIPRANKS
·
Aug 06

Tyra Biosciences delayed cancer data by one month, says JonesResearch

TIPRANKS
·
Aug 06

Tyra Biosciences falls 20% after pushing data readout to September from August

TIPRANKS
·
Aug 06

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)

TIPRANKS
·
Aug 05

Tyra Biosciences Q2 EPS $(0.69) Misses $(0.65) Estimate

Benzinga Earnings
·
Aug 05

Tyra Biosciences - Amends Sales Agreement on Aug 4, 2026 to Increase Maximum Offering Price for Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 05

Tyra Biosciences - May Offer and Sell up to $250 Mln of Common Stock Under Amended Sales Agreement - SEC Filing

THOMSON REUTERS
·
Aug 05

Tyra Biosciences Q2 FY26 Net Loss Widens to $45.56 Million; R&D Expenses Climb to $39.2 Million

Reuters
·
Aug 05

Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial

TIPRANKS
·
Jul 30

Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity

TIPRANKS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 19

Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential

TIPRANKS
·
Jul 15

Tyra Biosciences Initiated at Buy by Jones Trading

Dow Jones
·
Jun 17

Tyra Biosciences initiated with a Buy at JonesResearch

TIPRANKS
·
Jun 17

Tyra Biosciences Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $56

THOMSON REUTERS
·
Jun 17